Article
Antibodies from Sierra Leonean and Nigerian Lassa fever survivors cross-react with recombinant proteins representing Lassa viruses of divergent lineages.
Scientific reports - 29 Sept 2020
Heinrich Megan L, Boisen Matthew L, Nelson Diana K S, Bush Duane J, Cross Robert W, Koval Anatoliy P, Hoffmann Andrew R, Beddingfield Brandon J, Hastie Kathryn M, Rowland Megan M, Aimukanova Irina, Koval Sophia, Lathigra Raju, Borisevich Viktoriya, Momoh Mambu, Sandi John Demby, Goba Augustine, Odia Lkponmwosa, Baimba Francis, Aiyepada John O, Ebo Benevolence, Eromon Philomena, Ugwu Chinedu, Folarin Onikepe, Olumade Testimony, Onyechi MacDonald N, Etafo Johnson, Adeyemi Rashidat, Ella Elijah E, Aminu Maryam, Gomerep Simji S, Eke Matthew Afam, Ogunsanya Olusola, Akpede George O, Asogun Danny O, Okogbenin Sylvanus A, Okokhere Peter O, Holst Johan, Shaffer Jeffrey G, Schieffelin John S, Geisbert Thomas W, Saphire Erica Ollmann, Happi Christian T, Grant Donald S, Garry Robert F, Branco Luis M
Abstract excerpt
Lassa virus (LASV) is the causative agent of Lassa fever, an often-fatal hemorrhagic disease that is endemic in West Africa. Seven genetically distinct LASV lineages have been identified. As part of CEPI's (Coalition for Epidemic Preparedness Innovations) Lassa vaccine development program, we assessed the potential of the human immune system to mount cross-reactive and cross-protective humoral immune responses to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.